Monthly tegafur–uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study

Table 4 Results of a Cox proportional hazard model to identify the significant variables of disease-free survival

Variable	3-Year Relapse-Free Survival (%)	3-Year Relapse-Free Survival Analysis
Variable	3-Year Relapse-Free Survival (%)	P value	HR (95% CI)
Tumor Location
(< 6 vs. ≥6 cm)	64.3% vs. 86.9%	0.001	4.944 (1.922–12.721)
LNR
(≥0.3 vs. < 0.3)	63.1% vs. 85.4%	0.024	2.662 (1.136–6.236)
UFUR maintenance
With vs. Without	85.1% vs. 67.5%	0.024	0.371 (0.157–0.880)

Age (< 65 vs. ≥65 years), Sex (male vs. female), CEA (≥5 vs. < 5 ng/mL), ypTNM (T and N stage), Histologic Grade (Moderate & Well vs. Poor),BMI (underweight, normal and overweight),Histologic Type (Adenocarcinoma, Mucinous adenocarcinoma and Signet ring cell) and regimen of adjuvant chemotherapy (5FU or FOLFOX) were variables without significant P-value in forward stepwise regression
UFUR tegafur-uracil, LNR the ratio of metastatic lymph nodes to the total examined nodes number

ISSN: 1471-2407